Navigation Links
Experimental drug shows encouraging results in treating most common form of lung cancer
Date:11/1/2013

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

Dr. Edward Garon, director of thoracic oncology at UCLA's Jonsson Comprehensive Cancer Center, presented the preliminary results of a Phase 1B study of the new drug, called MK-3475, on Oct. 29 at the World Conference on Lung Cancer in Sydney, Australia.

The detailed interim data on safety and activity came from a cohort of 38 patients with non-small cell lung cancer who were treated previously for the disease without positive results. For the study, the patients received MK-3475 every three weeks.

Among the participants, 24 percent responded to the drug, with their tumors shrinking, and the median overall survival rate was 51 weeks. For those who responded, the median response duration the average amount of time their tumors remained shrunk had not been reached at the time of this analysis, so it is at least 62 weeks.

Based on this data, a Phase 2/3 trial comparing two different doses of MK-3475 to standard chemotherapy for lung cancer has begun enrolling patients.

Some cancer cells can evade detection by the immune system by expressing a protein called PD-L1, which interacts with the protein PD-1 to prevent the immune system from seeing the cancer as an invader. MK-3475, an anti-PD-1 immunotherapy drug made by Merck, allows the immune system to properly detect the cancer and to activate T cells the so-called "foot soldiers" of the immune system to attack and kill cancer cells.

The most commonly reported drug-related side effects in the study were rash (21 percent), skin itching (18 percent), fatigue (16 percent), diarrhea (13 percent) and joint pain (11 percent). Most side effects, however, were of low grade.

"These are early results, but we are very encouraged by what we've seen so far with this drug," Garon said. "Lung cancer patients who have disease that has grown after two prior therapies do not have many options, and we are cautiously optimistic that this might be a treatment that improves their chances in the future."

According to the American Cancer Society, approximately 1.4 million people die from non-small cell lung cancer every year. It is the most common type of lung cancer, representing approximately 85 percent of all lung cancer diagnoses.


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant
2. ASSURE study of experimental agent to raise HDL yields disappointing and surprising results
3. York physicists offer novel insight into experimental cancer treatment
4. Experimental Drug Shows Benefits Against Melanoma in Early Study
5. Experimental Drugs Show Promise Against Prostate Cancer
6. Experimental Drug Seems to Aid Memory in Mice With Alzheimers
7. Mayo Clinic finds experimental drug inhibits growth in all stages of common kidney cancer
8. Experimental Drug for Hepatitis C Promising, Studies Show
9. Experimental Vaccine Shows Promise for Ovarian Cancer
10. Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors
11. Experimental Staph Vaccine Fails to Work, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... , ... July 26, 2017 , ... Team Type 1 ... to medicine for everyone affected by diabetes, is excited to announce the 106 college ... Ambassador Program. , Established in 2005, the Team Type 1 Foundation has bestowed ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... dogs and cats has opened in Jupiter. The state of the art ... and class leading treatments with a goal of providing heart patients longer lives. ...
(Date:7/26/2017)... ... 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) ... development of pharmaceutical and consumer products, announces the operational numbers of its wholly-owned ... International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues of ...
(Date:7/26/2017)... ... 2017 , ... Wendy M. Musielak, a partner at the Andrew Cores Family Law ... Association’s third Vice President earlier this year. She will serve the membership in this capacity ... President, in accordance with the organization’s by-laws. , Musielak joined the Andrew ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or ... ways to improve asthma control in the population are not well described. In a ... Practice), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, 2017 ... ) announced today that it will report its second ... Thursday, July 27, 2017. ... July 27, 2017, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
Breaking Medicine Technology: